<DOC>
	<DOC>NCT03099200</DOC>
	<brief_summary>The purpose of this study is to compare productivity (in terms of work or daily activity) and generic and disease-specific health-related quality of life of participants with HER2 positive early breast cancer currently receiving adjuvant treatment (with chemotherapy and/or targeted HER2 therapy), with participants who have completed adjuvant parenteral therapy, and participants with HER2 positive metastatic breast cancer.</brief_summary>
	<brief_title>An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosed with early stage or metastatic (Stage IV) HER2positive breast cancer (confirmed by the study site physician). [HER2positive is defined as ImmunoHistoChemistry (IHC3+) and/or in situ hybridization (ISH) ≥2.0] Able to provide written, informed consent. Early Stage Breast Cancer (eBC) patients must have received at least 1 cycle of adjuvant anticancer therapy following surgery; metastatic breast cancer (mBC) patients must have received at least 1 cycle of treatment for their metastatic disease. Unwilling or unable to consent. Unable to complete written quality of life questionnaires Partcipants with Eastern Cooperative Oncology Group (ECOG) Performance Status ≥3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>